We show for the first time that there is a survival advantage of DBS surgery in advanced PD. The effect of potential bias factors is examined. The survival advantage may arise for several postulated reasons, ranging from improvement in axial functions, such as swallowing, to some as yet unrecognised benefit of reduction in dopaminergic medication. These findings are of great interest to both patients with PD and the health professionals considering the treatment options for patients with severe PD.
Long-term outcomes confirm that it is both safe and effective to perform STN DBS under general anesthesia. As part of patient choice, this option should be offered to all DBS candidates with advanced Parkinson disease to enable more of these patients to undergo this beneficial surgery.
Objectives: Deep brain stimulation for Parkinson’s disease (PD) utilises an implantable pulse generator (IPG) whose finite lifespan in non-rechargeable systems necessitates their periodic replacement. We wish to determine if there is any significant difference in longevity of 2 commonly used IPG systems; the Medtronic Kinetra, and the Medtronic Activa Primary Cell (PC), which has come to replace it. Methods: All patients with bilateral Subthalamic Nucleus stimulators for PD performed in our centre were included. Battery life was then assessed using a Kaplan-Meier approach and comparisons between the Kinetra and Activa PC batteries were performed using log-rank tests. Results: Complete data was available for 183 patients. There was a significant difference in the average battery duration with an estimated median battery life in the Kinetra cohort of 6.6 years (95% CI 6.4–6.7), compared to 4.5 years (95% CI 4.4–4.5) in the Activa PC cohort (p < 0.001). Conclusion: The Activa PC IPG demonstrates a significantly reduced battery life of 2.1 years, with a median battery life of 4.5 years in comparison to 6.6 years in the Kinetra IPG. Future technology developments should therefore be focused on improving the battery life of the newer IPG systems.
ObjectivesThe authors have previously reported on the technical feasibility of subthalamic nucleus deep brain stimulation (STN DBS) under general anesthesia (GA) with microelectrode recording (MER) guidance in Parkinsonian patients who continued dopaminergic therapy until surgery. This paper presents the results of a prospective cohort analysis to verify the outcome of the initial study, and report on wider aspects of clinical outcome and postoperative recovery.MethodsAll patients in the study group continued dopaminergic therapy until GA was administered. Baseline characteristics, intraoperative neurophysiological markers, and perioperative complications were recorded. Long-term outcome was assessed using selective aspects of the unified Parkinson’s disease rating scale motor score. Immediate postoperative recovery from GA was assessed using the “time needed for extubation” and “total time of recovery.” Data for the “study group” was collected prospectively. Examined variables were compared between the “study group” and “historical control group” who stopped dopaminergic therapy preoperatively.ResultsThe study group, n = 30 (May 2014–Jan 2016), were slightly younger than the “control group,” 60 (51–64) vs. 64 (56–69) years respectively, p = 0.043. Both groups were comparable for the recorded intraoperative neurophysiological parameters; “number of MER tracks”: 60% of the “study group” had single track vs. 58% in the “control” group, p = 1.0. Length of STN MER detected was 9 vs. 7 mm (median) respectively, p = 0.037. A trend towards better recovery from GA in the study group was noted, with shorter “total recovery time”: 60 (50–84) vs. 89 (62–120) min, p = 0.09. Long-term improvement in motor scores and reduction in l-dopa daily equivalent dose were equally comparable between both groups. No cases of dopamine withdrawal or problems with immediate postop dyskinesia were recorded in the “on medications group.” The observed rate of dopamine-withdrawal side effects in the “off-medications” group was 15%.ConclusionsThe continuation of dopaminergic treatment for patients with PD does not affect the feasibility/outcome of the STN DBS surgery. This strategy appears to reduce the risk of dopamine-withdrawal adverse effects and may improve the recovery in the immediate postoperative period, which would help enhance patients’ perioperative experience.
STN DBS insertion under GA can be performed without the need to withdraw dompaminergic treatment preoperatively. In this review the inadvertent continuation of medications did not affect the physiological localisation of the STN or the clinical effectiveness of the procedure. The continuation of dopamine therapy is likely to improve the perioperative experience for PD patients, avoid dopamine-withdrawal complications and improve recovery. A prospective study is needed to verify the results of this review.
Our findings suggest that STN-DBS is not necessarily associated with apathy in the PD population; however, more severe apathy appears to be associated with a higher level of disability due to PD and worse QOL, but no other clinico-demographic characteristics.
BackgroundA number of epidemiologic studies show a decreased risk of non-melanoma cancer in Parkinson's disease (PD). Cigarette smoking is less prevalent in PD and hence the risk of smoking related neoplasia such as lung and colon would be expected to be decreased in PD. A link is shown between decreased physical activity and colorectal cancer. Increased dietary intake of iron increases colorectal cancer risk and iron deposition in the basal ganglia is a feature of PD. Thus common mechanisms may be involved in both disorders. Our study looks at a cohort of surgically treated PD patients to see if there is an altered risk of colorectal cancer among them.MethodIn our population of patients fitted with a deep brain stimulator between 2002 and 2010, we searched for causes of death confirmed against death certificates and a histological diagnosis of colorectal cancer in the patient records.ResultsOf 22 patients who had died, 3 had a diagnosis colorectal cancer. 1 more died of a carcinoembryonic antigen positive cancer of unknown origin.DiscussionFrom UK national statistics, colorectal cancer accounts for between 2.7 and 3.2% of all deaths. Although the small number of deaths in our cohort requires careful interpretation of the results, 14% of our cohort having a diagnosis of colorectal cancer suggests that the lifetime risk of colorectal cancer is not reduced in PD patients. This observation merits further investigation in a larger cohort of PD patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.